CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Apyx Medical Q3 revenue beats estimates on AYON system demand

By Reuters News


Overview

  • US surgical aesthetics firm's Q3 revenue rose 9% yr/yr, beating analyst expectations

  • Q3 adjusted EBITDA turned positive and beat analyst estimates

  • Company reaffirmed full-year 2026 revenue guidance


Outlook

  • Apyx Medical reaffirms 2026 revenue guidance of $59.0 mln to $60.0 mln

  • Company expects 2026 gross margins between 63% and 65%

  • Company lowers 2026 operating expense guidance to $41.0 mln-$42.5 mln from under $45.0 mln


Result Drivers

  • SURGICAL AESTHETICS GROWTH - Revenue growth driven by increased sales of AYON system and higher international generator sales

  • PRODUCT LAUNCH - Full commercial launch of power liposuction handpiece for AYON system contributed to results

  • OEM DECLINE - OEM segment revenue fell due to lower sales volume to existing customers


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$14.03 mln

$13.29 mln (6 Analysts)

Q3 Net Loss

$1.81 mln

Q3 Adjusted EBITDA

$0.4 mln

Q3 Gross Margin

64.20%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Apyx Medical Inc is $6.00, about 131.7% above its November 4 closing price of $2.59


Reuters Recommended Reads

  • Nov 4 - Envista Q3 sales rise 3.2%, slightly beat estimates

  • Nov 4 - Evolus Q3 revenue rises 13% on toxin and HA gel growth

  • Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.